Skip to main content

Table 2 Demographic and clinical data of 22 patients with autoimmune rheumatic disease (AIRD) and positive cytomegalovirus antigenemia

From: Incidence of Cytomegalovirus Antigenemia in patients with autoimmune rheumatic diseases: a 3-year retrospective study

Female sex 19 (90%)
Age (years)a 39.4 ± 20.8
AIRD
 SLE 13 (59%)
 ANCA-associated Vasculitis 4 (18.2%)
 RA 2 (9%)
 Systemic sclerosis 1 (4.5%)
 Overlap syndrome 1 (4.5%)
 Anti-sintetase syndrome 1 (4.5%)
Diagnosis AIRDb Time (months) 10.5 (0–276)
Hospitalization causea
 Activity + Infection 11 (50%)
 Infection only 8 (36.5%)
 Activity only 3 (13.6%)
AIRD treatment
Maximum dose of corticosteroids in hospital (mg/ day)a 87.7 ± 52.5
 Corticosteroids dose above 1 mg /kg/ daya 19 (86.4%)
 Methylprednisolone Pulse Therapya 11 (50%)
Immunosuppressant medicationsa 11 (50%)
Site of CMV infectiona
 Lung 10 (45.4%)
 Cytopenia 9 (40.9%)
 Gastrointestinal tract 6 (27.3%)
Hospitalization timea(days) 41.9 ± 34.1
Hospitalization time until CMV-Ag be requesteda(days) 11.5 ± 12
Time of symptoms until CMV-Ag be requesteda(days) 7.8 ± 7.1
Time from the first positive CMV-Ag to specific treatment be starteda(days) 3.3 ± 3.1
Number of positive CMV-Ag nuclei after specific treatment
 With Ganciclovirb 15 (1–500)
 No ganciclovirb 7 (1–4)
Co-Infectionsa 16 (72.7%)
Polymicrobial Infections 5 (22.7%)
CMV reactivation during hospitalization 0
Prophylaxis after standard Ganciclovir treatment 0
  1. aMean ± standard deviation; bMedian (minimum and maximum); AIRD Autoimmune Rheumatic Diseases, CMV-Ag cytomegalovirus antigenemia, SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis